Risk factors for Epstein–Barr virus reactivation after renal transplantation: Results of a large, multi‐centre study-Reference-Cited by-同舟云学术

Risk factors for Epstein–Barr virus reactivation after renal transplantation: Results of a large, multi‐centre study

Published:2021-08-26 Issue:9 Volume:34 Page:1680-1688
ISSN:0934-0874
Container-title:Transplant International
language:en
Short-container-title:Transpl Int

Author:

Blazquez‐Navarro Arturo¹²³^ORCID,Dang‐Heine Chantip⁴,Wehler Patrizia²³,Roch Toralf²³,Bauer Chris⁵,Neumann Sindy⁶,Blazquez‐Navarro Rodrigo¹,Kurchenko Andriy⁷,Wolk Kerstin²⁸,Sabat Robert²⁸,Westhoff Timm H.³,Olek Sven⁹,Thomusch Oliver¹⁰,Seitz Harald¹¹,Reinke Petra²¹²,Hugo Christian¹³^ORCID,Sawitzki Birgit²,Or‐Guil Michal¹¹⁴^ORCID,Babel Nina²³^ORCID

Affiliation:

1. Systems Immunology Lab Department of Biology Humboldt‐Universität zu Berlin Berlin Germany

2. Berlin Institute of Health Center for Regenerative Therapies (BCRT): Berlin‐Brandenburger Centrum für Regenerative Therapien Charité – Universitätsmedizin Berlin Berlin Germany

3. Center for Translational Medicine Universitätsklinikum der Ruhr‐Universität Bochum Medizinische Klinik I Herne Germany

4. Clinical Study Center (CSC) Berlin Institute of Health, and Charité ‐ Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin Humboldt‐Universität zu Berlin Berlin Germany

5. MicroDiscovery GmbH Berlin Germany

6. numares AG Regensburg Germany

7. Department of Clinical Immunology and Allergology Bogolomets National Medical University Kiev Ukraine

8. Psoriasis Research and Treatment Center Charité – Universitätsmedizin Berlin Berlin Germany

9. Ivana Türbachova Laboratory for Epigenetics Epiontis GmbH Precision for Medicine Group Berlin Germany

10. Klinik für Allgemein‐ und Viszeralchirurgie Universitätsklinikum Freiburg Freiburg Germany

11. Fraunhofer Institute for Cell Therapy and Immunology, Branch Bioanalytics und Bioprocesses Leipzig Germany

12. Berlin Center for Advanced Therapies (BeCAT) Charité – Universitätsmedizin Berlin Berlin Germany

13. Universitätsklinikum Carl Gustav Carus Medizinische Klinik III ‐ Bereich Nephrologie Dresden Germany

14. Institute of Medical Immunology Charité – Universitätsmedizin Berlin Berlin Germany

Funder

Bundesministerium für Bildung und Forschung

Publisher

Frontiers Media SA

Subject

Transplantation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/tri.13982

Reference38 articles.

1. Epstein‐Barr virus‐infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients;Babcock GJ;J Exp Med,1999

2. Epstein‐Barr virus‐positive posttransplant lymphoproliferative disease after solid organ transplantation: pathogenesis, clinical manifestations, diagnosis, and management;Nijland ML;Transplant Direct,2016

3. Subclinical Epstein‐Barr virus Viremia among adult renal transplant recipients: Incidence and consequences;Bamoulid J;Am J Transplant,2013

4. BKV, CMV, and EBV interactions and their effect on graft function one year post‐renal transplantation: results from a large multi‐centre study;Blazquez‐Navarro A;EBioMedicine,2018

5. Modulation of angiogenic processes by the Human Gammaherpesviruses, Epstein – Barr Virus and Kaposi’s;Rivera‐Soto R;Front Immunol,2019

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epstein-Barr virus associated colitis in kidney transplant patients: a case series;Infectious Diseases;2024-03-09

2. Single-Center Outcomes of Epstein–Barr Virus DNAemia in Adult Solid Organ Transplant Recipients;Journal of Transplantation;2024-01-18

3. Prediction of herpes virus infections after solid organ transplantation: a prospective study of immune function;Frontiers in Immunology;2023-07-03

4. Short-term decreased post transplant lymphoproliferative disorder risk after kidney transplantation using two novel regimens;Transplant Immunology;2023-02

5. In vitro and in vivo evidence that the switch from calcineurin to mTOR inhibitors may be a strategy for immunosuppression in Epstein–Barr virus–associated post-transplant lymphoproliferative disorder;Kidney International;2022-12